

## SIGNATURE FOR THE PROGNOSIS OF BRAIN METASTASIS RELAPSE

The CNIO has developed a signature that allows the significant determination of the risk of relapse of brain metastasis after treatment.

Industrial partners are being sought to collaborate through a patent license agreement for the development and exploitation of the technology.

### Description

The inventors have found a method for the prognosis of brain metastasis relapse and to a kit useful in said prognosis based on a gene signature.

### Main innovations and advantages

The inventors have found that analyzing the expression levels of the genes of the signature of the present invention in an isolated sample from a subject who underwent treatment, for example brain surgery, constitutes a reliable method for the prognosis of brain metastasis relapse in the subject.

The signature of the present invention is therefore the basis of a reliable method and kit for the prognosis of brain metastasis relapse after treatment, and more particularly, after brain surgery.

### Intellectual property

Patent title:

SIGNATURE FOR THE PROGNOSIS OF BRAIN METASTASIS RELAPSE

Applicant:

Spanish National Cancer Research Center (CNIO)

Patent application:

WO/2025/008525

Patent application suitable for entering national phases

### For more information, please contact:

Technology Transfer and Valorization Office  
Centro Nacional de Investigaciones Oncológicas  
C/ Melchor Fernández Almagro, 3. 28029 Madrid  
Spain

[technologytransfer@cnio.es](mailto:technologytransfer@cnio.es)

[www.cnio.es](http://www.cnio.es)

@CNIO\_Cancer



cnio stopcancer

BECOME A  
CNIO FRIEND

HOPE RESEARCH  
LESS CANCER